What is a mandatory treatment for Lobular Carcinoma In Situ (LCIS)?

Lobular Carcinoma In Situ (LCIS) is classified as a non-invasive breast lesion and is considered a marker for an increased risk of developing breast cancer in the future rather than a true breast cancer itself. Therefore, the approach to management of LCIS typically involves observation rather than aggressive surgical treatments.

Resection without the need for negative margins is seen as a reasonable approach in cases where there are other risk factors or if the patient desires more definitive action. However, due to its non-invasive nature, many experts advocate for observation. Resection may be considered, but it is often not mandated since LCIS itself does not require immediate surgical intervention.

In the case where a patient prefers to decrease their risk of potential future malignancy, they might opt for preventive measures such as bilateral mastectomy, especially if other risk factors are present. However, this is not a mandatory treatment for LCIS itself.

Observation is often emphasized in guidelines as the standard approach, with patients monitored closely for any changes. Thus, while resection can be performed, specifically without the need for achieving negative margins, it does not constitute the required treatment for LCIS. This nuanced management reflects the understanding that while LCIS can indicate increased risk, it does